NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india) arrow 10188.95 -56.30 -0.55%
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Baxter International Inc. (NYSE: BAX)

 

BAX Share Price

Open 64.82 Change Price %
High 64.95 1 Day -0.10 -0.15
Low 64.20 1 Week 0.00 0.00
Close 64.47 1 Month 1.65 2.63
Volume 2679341 1 Year 17.65 37.70
52 Week High 65.70
52 Week Low 43.13
 
BAX Technical Analysis
4
As on 31st Oct 2017 BAX Share Price closed @ 64.47 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 55.52 & Buy for SHORT-TERM with Stoploss of 62.92 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 
NYSE USA Most Active Stocks
RAI 65.40 -2.23%
EMC 29.05 0.97%
GE 20.16 -1.22%
AKS 4.59 -21.54%
PCS 11.84 -0.92%
AMD 10.98 0.83%
WSH 47.18 -2.86%
JNS 14.17 -0.56%
XLS 24.66 -0.64%
SWY 35.10 -0.11%
 
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
TREX 109.45 25.65%
HZO 18.55 22.04%
SSD 55.74 14.62%
TBI 27.10 14.11%
SSTK 38.99 13.84%
KAI 113.60 13.09%
 
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
 
 
BAX
Daily Charts
BAX
Intraday Charts
BAX
Free Analysis
Premium
Service
 
BAX Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE65.17
RESISTANCE64.88
SUPPORT64.06
SUPPORT63.77
SUPPORT0.00
SUPPORT0.00
 
BAX Target for Month October
4th UP TARGET73.95
3rd UP TARGET70.91
2nd UP TARGET69.03
1st UP TARGET67.15
1st DOWN TARGET61.79
2nd DOWN TARGET59.91
3rd DOWN TARGET58.03
4th DOWN TARGET54.99
 
BAX Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
BAX Target for Year 2018
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
BAX Other Details
Segment EQ
Market Capital 36252073984.00
Sector Healthcare
Industry Medical Instruments & Supplies
Offical website http://www.baxter.com
 
BAX Address
BAX
One Baxter Parkway
Deerfield, IL 60015
United States
Phone: 224-948-2000
Fax: 224-948-1813
 
BAX Latest News
 
Your Comments and Response on Baxter International Inc.
 
BAX Business Profile
Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.
 
© 2005-2018 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service